Serplulimab interacts in the following cases:
The use of systemic corticosteroids or immunosuppressants before starting serplulimab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy. However, systemic corticosteroids or other immunosuppressants can be used to treat immune-mediated adverse reactions after starting serplulimab.
There are insufficient data and no dose recommendation can be made in patients with severe (CRCL=15-29 ml/min) renal impairment.
There are insufficient data in patients with moderate (bilirubin >1.5 to 3 × ULN and any AST) hepatic impairments and no data are available in severe (bilirubin >3 × ULN and any AST) hepatic impairments. No dose recommendation can be made for patients with moderate or severe hepatic impairment.
There is no data on the use of serplulimab in pregnant women. Animal studies have demonstrated that inhibition of the PD-1 pathway causes embryofoetal toxicity. Human IgG is known to cross the placental barrier and serplulimab is an IgG4; therefore, it has the potential to be transmitted from the mother to the developing foetus. Serplulimab is not recommended during pregnancy and in women of childbearing potential not using contraception.
It is unknown whether serplulimab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon; consequently, a risk to the breast-fed infant cannot be excluded during this short period. Afterwards, serplulimab could be used during breast-feeding if clinically needed.
Women of childbearing potential should use effective contraception during treatment and for at least 6 months after the last dose of serplulimab.
Studies to evaluate fertility have not been performed. Thus, the effect of serplulimab on male and female fertility is unknown.
Serplulimab has minor influence on the ability to drive and use machines. Because of potential adverse reactions such as fatigue, patients should be advised to use caution when driving or operating machinery until they are certain that serplulimab does not adversely affect them.
The safety of serplulimab in combination with chemotherapy is based on pooled data in 1 343 patients. The most common adverse reactions were anaemia (80.2%), neutropenia (74.5%), leukopenia (71.6%), thrombocytopenia (53.8%), nausea (44.4%), decreased appetite (36.0%), alopecia (33.6%), hypoproteinaemia (31.3%), asthenia (29.9%), and vomiting (28.2%).
The most common Grade ≥ 3 adverse reactions were neutropenia (46.2%), leukopenia (27.3%), anaemia (25.8%), thrombocytopenia (15.3%), hyponatraemia (6.9%), and pneumonia (5.6%).
The most common serious adverse reactions were thrombocytopenia (8.4%), pneumonia (6.6%), neutropenia (6.0%), leukopenia (5.9%), anaemia (4.5%), and pneumonitis (3.3%).
The most common immune-mediated adverse reactions were hypothyroidism (11.5%), immune-mediated skin reactions (7.6%), hyperthyroidism (7.1%), immune-mediated lung disease (5.5%), abnormal liver function (3.2%), immune-mediated nephritis and renal insufficiency (3.1%), and immune-mediated colitis (1.6%).
Serplulimab was discontinued due to adverse reactions in 8.1% of patients. The most common adverse reactions leading to treatment discontinuation were pneumonitis (1.6%) and pneumonia (1.3%).
Adverse reactions reported in clinical trial and in post-marketing experience are listed by system organ class and frequency (see table). Unless otherwise stated, the frequencies of adverse reactions are based on all-cause adverse event frequencies identified in trials in which 1343 patients were exposed to serplulimab in combination with chemotherapy.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Adverse reactions in patients treated with serplulimab*:
| Serplulimab in combination with chemotherapy | |
| Infections and infestations | |
| Very common | pneumoniaa |
| Common | urinary tract infectionb, respiratory tract infectionc, skin infection |
| Uncommon | septic shock |
| Rare | gastrointestinal infection, meningoencephalitis herpetic |
| Blood and lymphatic system disorders | |
| Very common | neutropenia, leukopenia, anaemia, thrombocytopenia, lymphopenia |
| Common | coagulation function test abnormald, granulocytopenia, febrile neutropenia |
| Uncommon | lymphadenitis |
| Immune system disorders | |
| Common | infusion-related reactione |
| Uncommon | anaphylactic reaction |
| Endocrine disorders | |
| Very common | hypothyroidismf, hyperthyroidismg, hyperglycaemia or type 1 diabetes mellitush |
| Common | thyroiditisi |
| Uncommon | adrenal insufficiencyj, other thyroid disorderk, hypophysitis, thyroid function test abnormall, hypoparathyroidism |
| Rare | hyperadrenocorticism |
| Metabolism and nutrition disorders | |
| Very common | hyperlipidaemia, decreased appetite, hypoproteinaemia, hyperuricaemia, electrolyte imbalancem, weight decreased |
| Common | hypoglycaemia |
| Uncommon | lipoprotein abnormal |
| Psychiatric disorders | |
| Very common | insomnia |
| Nervous system disorders | |
| Common | vertigo, paraesthesia, headache, dizziness, neuropathy peripheraln |
| Uncommon | vertigo, immune-mediated encephalitis°, neurotoxicity, cerebral infarction, taste disorder, memory impairment |
| Rare | motor dysfunction, myasthenia gravis, myasthenic syndrome |
| Eye disorders | |
| Uncommon | vision blurred, keratitis, conjunctivitis |
| Cardiac disorders | |
| Very common | arrhythmiap |
| Common | sinus tachycardia, conduction defectsq, sinus bradycardia, cardiac failurer, troponin increased, myocardial injury |
| Uncommon | myocardial ischaemia, pericardial effusion, myocarditis |
| Rare | cardiomyopathy |
| Vascular disorders | |
| Common | hypertension, vasculitis, hypotension |
| Uncommon | venous thrombosis |
| Respiratory, thoracic and mediastinal disorders | |
| Very common | cough, chest pain |
| Common | pneumonitiss, dyspnoea, dysphonia, pulmonary embolism |
| Uncommon | respiratory failure |
| Gastrointestinal disorders | |
| Very common | nausea, constipation, diarrhoea, vomiting |
| Common | dysphagia, abdominal pain, flatulence, gastrointestinal disordert, stomatitis, dyspepsia, dry mouth, gastritis |
| Uncommon | enteritisu, immune-mediated pancreatitis, gingival bleeding, oesophagitis, gastric ulcer |
| Hepatobiliary disorders | |
| Very common | alanine aminotransferase increased, aspartate aminotransferase increased |
| Common | gamma-glutamyltransferase increased, hyperbilirubinaemia, liver injuryv |
| Skin and subcutaneous tissue disorders | |
| Very common | rashw, alopecia |
| Common | pruritus, dermatitisx |
| Uncommon | pigmentation disorder, psoriasis, dry skin, hyperhidrosis |
| Rare | toxic epidermal necrolysis |
| Musculoskeletal and connective tissue disorders | |
| Very common | musculoskeletal pain |
| Common | arthritis |
| Rare | myositisy |
| Renal and urinary disorders | |
| Very common | protein urine present, blood creatinine increased |
| Common | blood urea increased, haematuria, renal injuryz |
| Uncommon | dysuria, pollakiuria |
| General disorders and administration site conditions | |
| Very common | pyrexia, asthenia |
| Common | malaise, oedema |
| Uncommon | chills |
| Investigations | |
| Common | blood alkaline phosphatase increased, myoglobin blood increased, blood creatine phosphokinase increased, amylase increased |
| Uncommon | lipase increased |
* Adverse reaction frequencies presented in Table 2 may not be fully attributable to serplulimab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.
The following terms represent a group of related events that describe a medical condition rather than a single event:
a Includes pneumonia, lung abscess.
b Includes urinary tract infection, asymptomatic bacteriuria, white blood cells urine positive.
c Includes upper respiratory tract infection, pharyngotonsillitis, tonsillitis, influenza-like illness, lower respiratory tract infection.
d Includes activated partial thromboplastin time prolonged, activated partial thromboplastin time, activated partial thromboplastin time shortened, international normalised ratio decreased, prothrombin level increased, coagulopathy, hypercoagulation.
e Includes drug hypersensitivity, infusion-related reaction.
f Includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine free decreased, thyroxine decreased, central hypothyroidism, tri-iodothyronine decreased, tri-iodothyronine free decreased, immune-mediated hypothyroidism.
g Includes hyperthyroidism, blood thyroid stimulating hormone decreased, thyroxine increased, tri-iodothyronine increased, tri-iodothyronine free increased, thyroxine free increased, immune-mediated hyperthyroidism.
h Includes hyperglycaemia, type 1 diabetes mellitus, blood glucose increased, type 2 diabetes mellitus, impaired fasting glucose, diabetic ketoacidosis, blood ketone body increased, glucose tolerance impaired, ketoacidosis, glycosuria.
i Includes thyroid disorder, thyroiditis.
j Includes adrenal insufficiency, cortisol decreased.
k Includes euthyroid sick syndrome, ultrasound thyroid abnormal.
l Includes anti-thyroid antibody positive, thyroglobulin increased.
m Includes hyponatraemia, hypocalcaemia, hypokalaemia, hypomagnesaemia, hypophosphataemia, hypochloraemia, hyperphosphataemia, hyperkalaemia, hypermagnesaemia, hypercalcaemia.
n Includes neuropathy peripheral, peripheral sensorimotor neuropathy, immune-mediated neuropathy.
° Includes immune-mediated encephalitis, encephalitis autoimmune.
p Includes supraventricular extrasystoles, supraventricular tachycardia, arrhythmia, ventricular extrasystoles, arrhythmia supraventricular, atrial fibrillation, atrial tachycardia, bradyarrhythmia, early repolarisation syndrome, ventricular arrhythmia, palpitations, electrocardiogram abnormal.
q Includes atrioventricular block first degree, bundle branch block right, atrial conduction time prolongation, bundle branch block left, defect conduction intraventricular.
r Includes cardiac failure, cardiac failure acute, left ventricular failure, cardiopulmonary failure, N terminal prohormone brain natriuretic peptide increased.
s Includes immune-mediated lung disease, pneumonitis, interstitial lung disease.
t Includes acquired trachea-oesophageal fistula, gastrointestinal haemorrhage, gastrointestinal disorder, intestinal obstruction.
u Includes enteritis, enteritis infectious, immune-mediated enterocolitis, colitis, colitis ulcerative, enterocolitis, duodenitis.
v Includes hepatic function abnormal, drug-induced liver injury, liver injury, immune-mediated hepatitis, immune-mediated hepatic disorder**, hepatic failure**.
w Includes rash, rash maculo-papular, eczema, drug eruption, erythema, skin toxicity, palmar-plantar erythrodysaesthesia syndrome.
x Includes autoimmune dermatitis, dermatitis, dermatitis allergic, dermatitis bullous, seborrhoeic dermatitis.
y Includes myositis**, immune-mediated myositis.
z Includes acute kidney injury, renal failure, renal impairment, renal injury, chronic kidney disease, creatinine renal clearance decreased, immune-mediated nephritis.
** Post-marketing event.
Serplulimab is associated with immune-mediated adverse reactions. The data for the following immune-mediated adverse reactions are based on 2 086 patients who received serplulimab monotherapy (n=292) or in combination with other medicinal products (n=1 794) across nine doses (0.3, 1, 3, 10 mg/kg every 2 weeks, 4.5 mg/kg every 3 weeks, 200 mg every 2 weeks, 300 mg every 3 weeks, 400 mg every 4 weeks, or 600 mg every 6 weeks) in ten clinical trials. The management guidelines for these adverse reactions are described in sections 4.2 and 4.4.
Immune-mediated lung disease occurred in 4.9% of patients, including Grade 3, 4 or 5 in 1.2%, 0.2%, and 0.3% of patients, respectively. The median time to onset was 4.40 months (range: 0.03-34.53 months). The median duration was 1.76 months (range: 0.10-13.34 months). 2.5% of patients received high-dose corticosteroid treatment. Immune-mediated lung disease led to discontinuation in 1.3% of patients.
Immune-mediated colitis occurred in 2.0% of patients, including Grade 3 in 0.6% of patients and Grade 5 in <0.1% of patients. The median time to onset was 3.35 months (range: 0.03-30.55 months). The median duration was 0.43 months (range: 0.03-8.94 months). 0.7% of patients received high-dose corticosteroid treatment. Immune-mediated colitis led to discontinuation in 0.2% of patients.
Hepatitis occurred in 0.8% of patients, including Grade 3 in 0.3% of patients, Grade 4 in 0.1% of patients, and Grade 5 in 0.1% of patients. The median time to onset was 2.48 months (range: 0.36-26.78 months). The median duration was 0.95 months (range: 0.10-8.48 months). 0.4% of patients received high-dose corticosteroid treatment. Hepatitis led to discontinuation in 0.3% of patients. Abnormal liver function occurred in 3.7% of patients, including Grade 3 in 0.8% of patients, and Grade 4 in 0.1% of patients. The median time to onset was 2.30 months (range: 0.07-45.31 months). The median duration was 1.31 months (range: 0.26-17.54 months). 0.5% of patients received high-dose corticosteroid treatment. Abnormal liver function led to discontinuation in 0.2% of patients.
Immune-mediated nephritis and renal insufficiency occurred in 3.0% of patients, including Grade 3 in 0.3% of patients and Grade 4 in <0.1% of patients. The median time to onset was 2.83 months (range: 0.23-17.77 months). The median duration was 1.48 months (range: 0.13-17.94 months). 0.4% of patients received high-dose corticosteroid treatment. Immune-mediated nephritis and renal insufficiency led to discontinuation in 0.2% of patients.
Hypothyroidism occurred in 11.7% of patients, including Grade 3 in 0.2% of patients. The median time to onset was 3.83 months (range: 0.46-34.10 months). The median duration was 2.73 months (range: 0.13-29.08 months). 6.7% of patients received thyroid hormone replacement therapy. <0.1% patients discontinued serplulimab due to hypothyroidism.
Hyperthyroidism occurred in 6.7% of patients, and there were no Grade ≥3 hyperthyroidism. The median time to onset was 2.73 months (range: 0.62-31.18 months). The median duration was 1.45 months (range: 0.07-17.77 months). No patients discontinued serplulimab due to hyperthyroidism.
Thyroiditis occurred in 0.7% of patients, and there were no Grade ≥3 thyroiditis. The median time to onset was 6.64 months (range: 0.99-13.50 months). The median duration was 1.30 months (range: 0.56-11.30 months). 0.2% of patients received thyroid hormone replacement therapy. No patients discontinued serplulimab due to thyroiditis.
Adrenal gland disorders occurred in 0.5% of patients, including Grade 3 in 0.1% of patients. The median time to onset was 6.24 months (range: 3.55-21.45 months). The median duration was 4.60 months. <0.1% of patients received high dose corticosteroid treatment. No patients discontinued serplulimab due to adrenal gland disorders.
Pituitary disorders occurred in 0.8% of patients, including Grade 3 in 0.1% of patients. The median time to onset was 6.72 months (range: 1.41-20.53 months). The median duration was 3.25 months. 0.2% of patients received high-dose corticosteroid treatment. Pituitary disorders led to discontinuation in 0.1% of patients.
Type 1 diabetes mellitus/hyperglycaemia occurred in 0.9% of patients, including Grade 3 in 0.4% of patients and Grade 4 in 0.1% of patients. The median time to onset was 4.34 months (range: 0.69-40.28 months). The median duration was 3.48 months (range: 0.53-10.68). 0.5% of patients received insulin replacement therapy. Type 1 diabetes mellitus/hyperglycaemia led to discontinuation in <0.1% of patients.
Immune-mediated skin reactions occurred in 7.8% of patients, including Grade 3 in 0.8% of patients, Grade 4 in <0.1% of patients, and Grade 5 in <0.1% of patients. The median time to onset was 2.96 months (range: 0.03-30.52 months). The median duration was 1.56 months (range: 0.07-19.06 months). 1.2% of patients received high-dose corticosteroid treatment. Immune-mediated skin reactions led to discontinuation in 0.5% of patients.
Immune-mediated pancreatitis occurred in 1.0% of patients, including Grade 3 in 0.3% of patients, Grade 4 in 0.1% of patients and Grade 5 in <0.1% of patients. The median time to onset was 2.86 months (range: 0.23-13.67 months). The median duration was 0.76 months (range: 0.16-10.12 months). 0.1% of patients received high-dose corticosteroid treatment. Immune-mediated pancreatitis led to discontinuation in 0.2% of patients.
Immune-mediated myocarditis occurred in 0.7% of patients, including Grade 3 in 0.1% of patients, Grade 4 in <0.1% of patients and Grade 5 in 0.2% of patients. The median time to onset was 1.71 months (range: 0.26-20.70 months). The median duration was 0.79 months (range: 0.30-5.72 months). 0.5% of patients received high-dose corticosteroid treatment. Immune-mediated myocarditis led to discontinuation in 0.3% of patients.
Immune-mediated uveitis occurred in <0.1% of patients, which was Grade 1. The time to onset was 6.90 months. The duration of immune-mediated uveitis was 1.35 months. The event resolved for the patient.
Other clinically significant immune-mediated adverse reactions reported in patients who received serplulimab were as follows. Severe or fatal cases have been reported for some of these adverse reactions.
Blood and lymphatic system: anaemia, leukopenia, thrombocytopenia, neutropenia.
Nervous system: immune-mediated encephalitis, neuropathy peripheral, epilepsy, encephalopathy, peripheral sensorimotor neuropathy.
Eye disorders: vision blurred.
Cardiac/vascular: acute coronary syndrome, myocardial infarction, cardiac failure, cardiotoxicity, troponin increased, cardiac function test abnormal.
Respiratory, thoracic and mediastinal: dyspnoea, chronic obstructive pulmonary disease, respiratory failure.
Gastrointestinal: mouth ulceration, vomiting, proctitis, upper gastrointestinal haemorrhage.
General disorders and administration site conditions: asthenia, fatigue, pyrexia.
Other: panic disorder, abnormal behaviour, cholangitis acute, sepsis, peritonitis, blood alkaline phosphatase increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, n-terminal prohormone brain natriuretic peptide increased, blood cholesterol increased, electrolyte imbalance, chronic kidney disease, urinary tract inflammation.
Infusion-related reactions occurred in 1.7% of patients, including Grade 3 in 0.1% of patients and Grade 4 in 0.1% of patients. The median time to onset was 1.74 months (range: 0.03-34.04 months). The median duration was 0.07 months (range: 0.03-6.70 months). No patients discontinued serplulimab due to infusion-related reactions.
The proportions of patients who experienced a shift from baseline to a Grade ≥3 laboratory abnormality were as follows: 0.5% for platelet count decreased, 0.3% for neutrophil count decreased, 0.2% for blood creatine phosphokinase increased, 0.1% for white blood cell count decreased, 0.1% for troponin I increased.
No overall differences in safety were reported between elderly (≥65 years) and younger patients. Data for patients ≥75 years of age are too limited to draw conclusions on this population.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.